PumaRx Registry for RenovoCath delivery to solid tumors
Official title: A Multi-Center, Observational, Post-Marketing, Registry Study Following Patients With Solid Tumors Treated With Therapeutic Agents Via Localized Intra-Arterial Delivery Using the RenovoCath® Catheter
Run by RenovoRx · NCT06805461 · Data updated 2026-11-12
This registry follows adults with solid tumors to track how the RenovoCath catheter performs and how patients do after cancer medicines are delivered directly into tumors through arteries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | RenovoRx Industry-sponsored |
| Locations | 3 sites (Coral Gables, Florida and 2 other locations) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | September 3, 2029 |
| Study ends | September 3, 2029 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT06805461 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) diagnosed with a solid tumor who receive or plan to receive intra‑arterial therapy using RenovoCath and who are willing to provide informed consent and medical record access.
✕Probably not a fit
Patients who do not receive RenovoCath, have non‑solid (hematologic) cancers, are under 18, or cannot provide consent or medical records are unlikely to benefit from this registry's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, observational post‑marketing registry that records real‑world safety, device performance, and survival outcomes for patients treated with the RenovoCath intra‑arterial catheter. Up to 1,000 adult patients treated per the country‑specific Instructions for Use will be enrolled across an estimated ~100 participating sites. Medical records (including prior treatments and all localized IA administrations with RenovoCath) will be retrieved about four times and patients or families will be contacted periodically to capture survival data. Treatments are provided per routine clinical care and the registry collects outcome data without directing specific therapeutic interventions.
Why it matters
Potential benefit: If successful, this registry could clarify the real‑world safety profile and survival outcomes after RenovoCath‑facilitated intra‑arterial therapy, helping inform care decisions.
How similar studies have gone: Other intra‑arterial locoregional approaches (for example transarterial chemoembolization and hepatic arterial infusion) have shown benefit in selected solid tumors, but device‑specific evidence for RenovoCath is limited and being collected.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria: 1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure 2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records
Where it's running
-
Baptist Health South Florida
Coral Gables, Florida, United States Recruiting -
University of Pennsylvania Medical Center
Pittsburgh, Pennsylvania, United States Recruiting -
The University of Vermont Medical Center
Burlington, Vermont, United States Recruiting
Study contacts
- Study coordinator: Leesa M Gentry
- Email: lgentry@renovorx.com
- Phone: 650-284-4433
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.